Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
One Dose of H1N1 Vaccine Immunogenic in High Percentage of Youth Ages 10 to 17. Younger Children Likely Will Need Two Doses
American Family Physician, 10/02/09
Mitchell D – A single 15–microgram dose of a nonadjuvanted vaccine against 2009 H1N1 influenza generated a robust immune response in 76 percent of 10– to 17–year–olds eight to 10 days after immunization. A high percentage of adults ages 18 to 64 years had a robust immune response to a single 15–microgram dose of nonadjuvanted vaccine. The vaccines used in the adult clinical trials were manufactured by CSL Ltd., based in Melbourne, Australia, and Sanofi Pasteur Inc., (2–page PDF; About PDFs) based in Swiftwater, Pa. Similar results seen with Sanofi Pasteur's H1N1 vaccine for children ages 10 to 17 years represented good news in terms of vaccine supply and efficacy. Results were not as favorable, however, in younger children. A strong immune response was reported in 36 percent of kids 3 years to 9 years of age who received single 15–microgram dose of the H1N1 vaccine and in only 25 percent of children 6 months to 35 months old who received one such dose. Immune response likely would increase in all age groups closer to 21 days after vaccination. Children ages 6 months to 9 years likely will need two H1N1 doses 21 days apart. Healthy children ages 2 and older can receive live attenuated influenza vaccine, or LAIV, as a nasal spray. Inactivated seasonal flu vaccine and inactivated H1N1 vaccine likely can be administered on the same day via injections in different arms.
Related Articles
Update on 2009 pandemic influenza A (H1N1) virus
Cleveland Clinic Journal of Medicine, 10/05/09
Relevance Score: 99%
H1N1 vaccine shortage leaves doctors managing crowds, anxieties
American Medical News, 11/06/09
Relevance Score: 98%
H1N1 Vaccine Production, Availability Increasing Slowly
American Family Physician, 11/02/09
Relevance Score: 98%
Effectiveness and Cost-Effectiveness of Vaccination Against Pandemic Influenza (H1N1) 2009
Annals of Internal Medicine, 10/09/09
Relevance Score: 98%
H1N1 Vaccine Deliveries Begin. Early Doses to Arrive This Week
American Family Physician, 10/07/09
Relevance Score: 98%
Today in Family Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
The Association Between the Number of Prescription Medications and Incident Falls in a Multi-ethnic Population of Adult Type-2 Diabetes Patients: The Diabetes and Aging Study
Journal of General Internal Medicine, 12/09/09
Translational Research and Reproductive Senescence
The Female Patient, 12/09/09
Using group support to complement a task-based weight management programme in multi-ethnic localities of high deprivation
Patient Education and Counselling, 12/09/09
Today in Pediatrics...keeping you current
Receive free subspecialty "5-minute updates" via email
Paracetamol versus ibuprofen: A randomized controlled trial of outpatient analgesia efficacy for paediatric acute limb fractures
Emergency Medicine Australasia, 12/09/09
Children with asthma on inhaled corticosteroids managed in general practice or by hospital paediatricians; is there a difference?
Primary Care Respiratory Journal, 12/09/09
Pain expression in children with an intellectual disability
European Journal of Pain, 12/09/09
Today in Preventive Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Using group support to complement a task-based weight management programme in multi-ethnic localities of high deprivation
Patient Education and Counselling, 12/09/09
Detecting breast cancer in a general practice - Like finding needles in a haystack?
Australian Family Physician, 12/09/09
The Enhancing Secondary Prevention in Coronary Artery Disease trial
Canadian Medical Association Journal, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


